InsidersTradesSigma
Follow the Grace Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €44.6m. The latest transaction was disclosed on 19 August 2026 (Acquisition). Among the most active insiders: Opaleye Management Inc.. Every trade is accessible without an account.
Analysts rate Grace Therapeutics, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$6.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Grace Therapeutics, Inc. is a company focused on developing innovative therapies. It is listed on the XNAS market.